Therapeutic Advances in Endocrinology and Metabolism is a premier open-access journal published by SAGE Publications Ltd that has established itself as a leading platform for research in the field of endocrinology, diabetes, and metabolism. With a commitment to disseminating high-quality research, the journal aims to advance our understanding of therapeutic interventions and innovations in the management of endocrine disorders. Since its inception in 2010, it has garnered a strong reputation, attaining a Q1 quartile ranking in 2023 in its category and boasting a respectable Scopus rank of #53 out of 244, positioning it within the 78th percentile. As an open-access journal since 2019, Therapeutic Advances in Endocrinology and Metabolism ensures that valuable research findings are accessible to a global audience, fostering collaboration and knowledge sharing among researchers, clinicians, and students alike. The journal's multifaceted objectives encompass the publication of original research, reviews, and clinical studies that contribute to the evolving dialogue surrounding endocrine health. By delivering timely and robust content, it serves as an indispensable resource for those striving to make significant contributions to this vital area of medical science.

Lancet Diabetes & Endocrinology is a premier peer-reviewed journal, published by Elsevier Science Inc, dedicated to advancing the fields of endocrinology, diabetes, and metabolism. Established in 2013, this journal has quickly ascended to a position of notable prestige, reflected in its prestigious Q1 rank across various categories, including Endocrinology, Internal Medicine, and Diabetes & Metabolism. With an impressive impact factor and Scopus rankings placing it in the 99th percentile of its field, it serves as a vital resource for researchers, healthcare professionals, and students alike. The journal aims to disseminate high-quality research covering clinical and experimental aspects of metabolic and endocrine disorders, making it an indispensable tool for those looking to stay at the forefront of these rapidly evolving fields. With its focus on innovative depth and cutting-edge studies, Lancet Diabetes & Endocrinology continually fosters an international dialogue critical for advancements in diabetes and endocrinology.

BMC Endocrine Disorders is a leading open-access journal dedicated to advancing the field of endocrinology, diabetes, and metabolism. Published by BMC since 2001, this journal provides a vibrant platform for researchers to disseminate their findings across a wide array of topics related to endocrine health and disorders. With an impressive Q2 category ranking in both Endocrinology, Diabetes and Metabolism, and Medicine (miscellaneous) for 2023, it has positioned itself among the top-tier journals in its field, reflecting its commitment to high-quality research and discussions. The journal's accessibility enhances its reach and impact, ensuring that important findings are available to all stakeholders in the medical community. Researchers, healthcare professionals, and students alike will find valuable insights and updates that are crucial for both academic and practical applications within this dynamic field. The journal is actively welcoming submissions through 2024, facilitating continuous growth in the scientific discourse surrounding endocrine disorders.

Diabetes Metabolic Syndrome and Obesity is a leading open-access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing research in the fields of diabetes, metabolic syndrome, and obesity. Since its inception in 2008, the journal has aimed to disseminate high-quality, peer-reviewed articles that contribute to our understanding of these prevalent health issues, with a special focus on clinical practices, therapeutic advancements, and epidemiological studies. Boasting a commendable Q2 ranking in both Internal Medicine and Pharmacology for 2023, the journal is placed among the top tier of its category, with a Scopus ranking of #44 out of 167 in Internal Medicine and #124 out of 313 in Pharmacology. This positions the journal in the 73rd and 60th percentiles, respectively, highlighting its significance in the academic community. Researchers and professionals are encouraged to utilize this journal as a valuable resource for access to groundbreaking studies and developments in the treatment and management of diabetes and related metabolic disorders, contributing to global health improvements.

Annals of Pediatric Endocrinology & Metabolism, published by the Korean Society of Pediatric Endocrinology, is a vital resource for researchers, healthcare professionals, and students in the fields of endocrinology, diabetes, and pediatric health. With its commitment to open access since 2012, the journal facilitates the dissemination of groundbreaking research on pediatric endocrine disorders and metabolic diseases, ensuring that vital knowledge is accessible to a global audience. The journal maintains a reputable standing with a 2023 Scopus rank of #92 in Pediatrics and a Q3 quartile in Endocrinology, highlighting its impact on the field. Originating from South Korea, the journal fosters a collaborative network of researchers and advocates best practices in pediatric care through interdisciplinary studies. The Annals not only enhances scientific understanding but also emphasizes practical applications aimed at improving child health outcomes, making it an essential publication for academics and practitioners alike.

Revista Portuguesa de Endocrinologia Diabetes e Metabolismo is a pivotal journal dedicated to advancing the fields of endocrinology, diabetes, and metabolism. Published by the esteemed SOC PORTUGUESA ENDOCRINOLOGIA, DIABETES & METABOLISMO-SPEDM, this journal serves as a platform for the dissemination of high-quality research, clinical studies, and innovative practices within these related disciplines. With a commitment to providing insightful and impactful content, the journal aims to foster knowledge sharing among researchers, healthcare professionals, and students interested in the latest developments in endocrine disorders and metabolic diseases. Although currently not open access, the journal's comprehensive approach and rigorous peer-review process ensure that it remains a respected source of information for its readers in Portugal and beyond. With its address rooted in the heart of Lisbon, the Revista Portuguesa de Endocrinologia Diabetes e Metabolismo plays a vital role in enhancing the understanding and treatment of endocrine and metabolic conditions in the modern healthcare landscape.

Current Obesity Reports, an esteemed journal published by SPRINGER, serves as a pivotal platform for scholars and practitioners in the field of obesity research. With its ISSN of 2162-4968, this journal has been recognized within the competitive landscape of Medicine & Internal Medicine, achieving a commendable Scopus rank of #11 out of 167, placing it in the top 93rd percentile. Launched in 2012 and covering critical developments in obesity up to 2024, this journal synthesizes innovative research, evidence-based practices, and comprehensive reviews that cater to a diverse audience, from researchers to public health professionals. While currently not offering open access options, it remains dedicated to advancing knowledge and fostering discussions that address the multifaceted issues related to obesity, its public health implications, and treatment methodologies. For those involved in tackling obesity challenges, Current Obesity Reports stands as a vital resource, contributing significantly to the discourse and scholarship in the field.

ENDOCRINE JOURNAL, published by the Japan Endocrine Society, is a pivotal resource for researchers and professionals in the field of endocrinology, diabetes, and metabolism. With a long history dating back to 1954, this journal encompasses a comprehensive range of topics including hormonal regulation, pathophysiology of endocrine diseases, and innovative therapeutic approaches. Despite its classification as open access, the journal remains a beacon of knowledge, with impressive rankings—Q2 in Endocrinology, Diabetes and Metabolism and Q3 in Endocrinology for 2023—ensuring it is a respected source in the academic community. It serves as a critical platform for the dissemination of cutting-edge research, encouraging collaboration and facilitating advancements in understanding complex endocrine disorders. By subscribing to this journal, researchers and students gain access to seminal studies, clinical insights, and a wealth of information that drives this vital field forward.

DIABETES RESEARCH AND CLINICAL PRACTICE, published by Elsevier Ireland Ltd, is a leading peer-reviewed journal in the realms of endocrinology, diabetes, and internal medicine. With a prestigious Q1 classification across several categories, including Endocrinology, Diabetes and Metabolism, and Internal Medicine, this journal is recognized for its impactful contributions to advancing knowledge and clinical practice in diabetes care, boasting an impressive impact factor that underscores its significance in the academic community. Spanning from 1985 to 2024, this journal not only disseminates high-quality research but also serves as a critical resource for healthcare professionals, researchers, and students alike who are focused on addressing the global diabetes epidemic. With its comprehensive scope and commitment to fostering innovative findings, DIABETES RESEARCH AND CLINICAL PRACTICE remains at the forefront of its field, fostering collaboration and discovery to improve patient outcomes.

Diabetologie und Stoffwechsel is a prominent academic journal specializing in the fields of endocrinology, diabetes, and metabolism, published by GEORG THIEME VERLAG KG. Since its inception in 2006, this German journal has strived to disseminate cutting-edge research and innovative findings that advance the understanding of metabolic disorders and the management of diabetes. With an ISSN of 1861-9002 and an E-ISSN of 1861-9010, it caters to a diverse audience ranging from researchers to healthcare professionals and students in the medical field. While it currently holds a Q4 ranking in the 2023 Scopus quartiles for its area, the journal serves as a critical platform for emerging insights and discussions impacting diabetes care and research, fostering collaboration and knowledge-sharing in a rapidly evolving landscape. The convergence of its coverage until 2024 signifies a commitment to ongoing exploration into the complexities of metabolic health, making it a valuable resource for anyone passionate about these vital areas of health.